Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01847495
Recruitment Status : Withdrawn (no patients enrolled)
First Posted : May 7, 2013
Last Update Posted : February 23, 2018
Information provided by (Responsible Party):
Arica Hirsch, MD, Advocate Health Care

Brief Summary:

The purpose of this study is to determine the effects of CyberKnife stereotactic body radiotherapy in combination with irinotecan chemotherapy in patients with colon or rectal cancer that has spread to the liver.

Conventional radiation therapy has a limited role in the treatment of patients with liver metastases because the radiation doses are limited by liver toxicity. The CyberKnife system is a type of radiation machine that precisely focuses large doses of x-rays on the tumor, so that injury from radiation to the nearby normal tissue will be minimal. It is approved by the U.S. Food and Drug Administration to treat tumors, lesions and conditions anywhere in the body when radiation therapy is required. While the device is no longer classified as "investigational", the best treatment dose and times are still being evaluated.

Chemotherapy delivered with radiation therapy can increase the effectiveness of treatment, and may allow for a lower dose of radiation therapy to be utilized, thereby limiting negative side effects.

In this study, patients will receive Cyberknife radiosurgery directed to liver metastasis for 3-5 treatments, given every other day. Irinotecan 40mg/m2 will be administered intravenously daily for 3-5 days (5 treatments within 10 elapsed days), and prior to radiation therapy. Patients will have follow-up visits at months 1,2,4,6,9,12,15,18, 24, 30, 36, and every 6 months thereafter for 3 years.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Drug: Irinotecan Radiation: CyberKnife Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Evaluation of Low-dose Irinotecan and Cyberknife® Stereotactic Body Radiotherapy in the Treatment of Patients With Colorectal Cancer and Limited Liver Metastasis
Study Start Date : October 2013
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2025

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Low-Dose Irinotecan & CyberKnife SBRT
Irinotecan 40mg/m2 x 3-5 days + CyberKnife SBRT 45-60Gy x 3-5 fractions
Drug: Irinotecan
40mg/m2 x 3-5 days
Other Names:
  • Camptosar
  • Irinotecan Hydrochloride
  • Irinotecan HCl
  • CPT-11

Radiation: CyberKnife
45-60 Gy for 3-5 days CyberKnife SBRT to liver metastasis within 10 elapsed days. Irinotecan will be administered on the same day, prior to SBRT.
Other Name: Stereotactic Radiosurgery

Primary Outcome Measures :
  1. Number of participants with adverse events related to toxicities from concurrent SBRT and irinotecan [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Tumor response rate [ Time Frame: 3 years ]
  2. Progression free survival [ Time Frame: 3 years ]
  3. Overall survival [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Age>18 years
  • Histologically confirmed primary colorectal cancer
  • Stage IV colorectal cancer with </= 3 metastases, up to 5cm in size.
  • CT scan or MRI of the abdomen with contrast, 60days prior to enrollment
  • If patient is allergic to contrast, imaging without contrast is acceptable
  • Positron-Emission Tomography 60 days prior to enrollment
  • No additional sites of metastasis at the time of protocol enrollment. History of other sites of metastasis that are currently controlled are acceptable.
  • No malignant ascites
  • At least 4 weeks from any chemotherapy
  • No prior liver radiation therapy
  • ECOG performance status 0-1
  • Life expectancy>3months
  • Laboratory evaluations completed 60 days prior to treatment including CMP, CBC with differential, liver function test, and prothrombin time.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01847495

Layout table for location information
United States, Illinois
Advocate Lutheran General Hospital
Park Ridge, Illinois, United States, 60068
Sponsors and Collaborators
Advocate Health Care
Layout table for investigator information
Study Chair: Arica Hirsch, MD Advocate Lutheran General Hospital
Study Chair: James Ruffer, MD Advocate Lutheran General Hospital
Study Chair: Jacob Bitran, MD Advocate Lutheran General Hospital
Study Chair: Edward S James, M.D. Advocate Lutheran General Hospital

Layout table for additonal information
Responsible Party: Arica Hirsch, MD, Principal Investigator, Advocate Health Care Identifier: NCT01847495    
Other Study ID Numbers: 5443
First Posted: May 7, 2013    Key Record Dates
Last Update Posted: February 23, 2018
Last Verified: February 2018
Keywords provided by Arica Hirsch, MD, Advocate Health Care:
Stage IV Colorectal Carcinoma
Liver metastasis
Stereotactic Body Radiotherapy
Irinotecan HCl
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Neoplasm Metastasis
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents